|
⚲
|
| Keyboard |
| Aquilo Capital Management LLC
✚
|
|
|---|---|
| CRD # | 153022 |
| SEC # | 801-111633 |
| CIK # | 0001591986 |
| AUM | |
| Employees | 5 (100% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 415-635-0140 |
| Address | One Letterman Drive San Francisco, CA 94129 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/26/2024) [Brochure] |
|---|
Item 5. Fees and Compensation Compensation for Advisory Services – Core Fund and Offshore Fund. Performance Allocation and Management Fees Beginning February 1, 2020, the Core Fund currently offers only a limited number of Series A Interests to potential investors who meet the Qualified Purchasers definition under Section 2(a)(51)(A) of the Investment Company Act of 1940. Series B and C Interests are only available to existing Series B and C investors that invested in the Core Fund before February 1, 2020 (collectively, the Series A, B & C Interests are the Core Fund “Series of Interests”). Beginning February 1, 2020, the Offshore Fund currently only offers a limited number of Tranche A Shares (“Tranche Shares”) to potential investors who meet the Qualified Purchasers definition under Section 2(a)(51)(A) of the Investment Company Act of 1940. As investment adviser to the Core Fund and the Offshore Fund, Aquilo receives management fees in advance at an annual rate ranging from 1.5% to 1.75% (depending on the Series of Interests or Tranche Shares) of the value of the underlying investors' capital account balance of the Core Fund as of the first business day of each calendar quarter. This management fee is deducted from Core Fund assets and is prorated for any investment period that is less than a full calendar quarter. In addition to management fees, Aquilo is entitled to receive a performance allocation ranging from 15% to 20% (depending on the Series of Interests or Tranche Shares) of the net profits of the Core Fund attributable to the capital account balance of each underlying investor. Aquilo, at its discretion, can waive or reduce the management fee and/or the performance allocation for any of the investors. A more detailed description of the pricing structure associated with each Series of Interests and Tranche Shares and investor requirements is available within the Confidential Offering Circular for the Core Fund and the Private Offering Memorandum for the Offshore Fund. Compensation for Advisory Services – LO Fund and LO Offshore Fund Performance Allocation and Management Fees The LO Fund offers a limited number of offering interests (“Offering Interests”) to potential investors who meet the Qualified Purchasers definition under Section 2(a)(51)(A) of the Investment Company Act of 1940. Beginning May 1, 2020, the LO Offshore Fund offers a limited number of shares that are issued in different series (“Series of Shares”) to each new potential investor who meets the Qualified Purchasers definition under Section 2(a)(51)(A) of the Investment Company Act of 1940. As investment adviser to the LO Fund and the LO Offshore Fund, Aquilo receives in advance a quarterly management fee at an annual rate of 1.0% of the value of the underlying investors’ capital account balance of the LO Fund as of the first business day of each calendar quarter. This management fee is deducted from the LO Fund assets and is prorated for any investment period that is less than a full calendar quarter. Aquilo Capital Management, LLC – ADV Part 2A Page 5 Fees Relating to Terminations and Withdrawals Relationships with Aquilo’s investment fund clients are terminable on the dissolution of the Funds or on Aquilo’s withdrawal as the general partner or adviser. With respect to terminating the advisory relationship, investors in the Funds generally can, on at least 60 days’ prior written notice, withdraw/redeem up to half of their capital account balance as of the end of any calendar quarter. If investors desire to withdraw/redeem their entire capital account balance, it will take at least 3 consecutive calendar quarters with the half limit being applied to the first two consecutive calendar quarters to fully withdraw/redeem that balance. However, if the remainder is not withdrawn/redeemed on the third consecutive calendar quarter, then the half withdrawal/redemption restriction again applies to the next time a withdrawal/redemption occurs. Investors in Series B and C of the Core Fund will be subject to withdrawal fees of either 3% or 5% for withdrawal of investments made within a specified period in accordance with each Fund’s documents. If an investor in any of the Funds is permitted by Aquilo to withdraw funds on a date other than a permitted withdrawal date, Aquilo can require the investor to pay an additional withdrawal fee of up to $5,000. The withdrawal fees described above will be deducted from the capital account balance otherwise payable to the withdrawing investor, will be included as income in the profits and losses of the other capital accounts, and can be reduced or waived by Aquilo. The withdrawal fees will not be charged, however, on any withdrawals relating to an amendment of the fund’s partnership agreement or any expulsion, or withdrawals relating to certain “key person” events. In all cases, investors and client accounts bear expenses, the pro rata portion of the management fee and the performance allocation or carried interest through the date of termination or withdrawal. An investment fund does not refund any management fee previously paid to an investor who withdraws from that fund on a date other than the last day of a quarter. Expenses Each client account is responsible for its own costs and expenses, including, but not limited to, trading costs and expenses (such as brokerage commissions, expenses related to short sales, and clearing and settlement charges), ongoing legal, accounting and bookkeeping fees and expenses, and the fees and expenses charged by any fund administrator for its accounting, bookkeeping, and other services. Aquilo generally bears its own operating, general, administrative, and overhead costs and expenses other than the expenses described above. Securities brokerage ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/26/2024) [Brochure] |
|---|
Item 7. Types of Clients Aquilo is organized and serves as the general partner and/or discretionary investment adviser to private investment funds. Aquilo may decide in the future to provide advice to separately managed accounts and to other private funds. Aquilo generally requires investors in the Core Fund and Offshore Fund to make a minimum initial investment of at least $1,000,000. Aquilo generally requires investors in the LO Fund and LO Offshore Fund to make a minimum initial investment of at least $5,000,000. Aquilo generally requires a minimum of $100,000,000 to open a separately managed account. The minimum contribution and investor requirements can be waived by Aquilo at its sole discretion. Investors generally must be “accredited investors” under Regulation D, who are also “Qualified Purchasers” under Section 2(a)(51)(A) of the Investment Company Act of 1940, as amended. Aquilo generally requires investors to make representations concerning their financial sophistication and ability to bear the risk of loss of their entire investment in a fund. Aquilo Capital Management, LLC – ADV Part 2A Page 8 |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Aquilo Capital Special Opportunity LP | [2021-03-31] | 16.2 M | 19.4 M |
| Filed 2023-08-23 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| Other | Aquilo Capital Lo LP | [2017-08-07] | 212.5 M | 87.6 M |
| Filed 2024-11-19 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Finder's Fee $1,344,084 · Net Assets Decline to Disclose | ||||
| HF | Aquilo Capital LP | [2015-04-06] | 257.0 M | 170.0 M |
| Filed 2024-11-19 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Finder's Fee $2,091,593 · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 257.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 257.6 |
| By Discretionary | ||
| Discretionary | 4 | 257.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 257.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 50.2 | |
| United States Persons | 207.4 | |
| Total | 4 | 257.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Marc Schneidman | Executive Officer | 4 | 2 | |
| Aquilo Capital Management LLC | Executive Officer | 3 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001591986] | |
| 3 | [0001591986] | |
| 4 | [0001591986] | |
| SC 13G | [0001591986] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 254900J03UBQSFDMNU40 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Aquilo Capital LP | |
| Aquilo Capital Management LLC | |
| Spero Therapeutics Inc | |
| Palvella Therapeutics Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-09-22 | Sell | 1,335,512 | $2.25 | 3,004,902 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-09-22 | Sell | 566,284 | $2.25 | 1,274,139 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-04-26 | Buy | 39,727 | $5.24 | 208,169 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-03-30 | Buy | 16,885 | $8.79 | 148,419 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-03-30 | Buy | 33,115 | $8.79 | 291,081 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-03-14 | Buy | 8,006 | $7.63 | 61,086 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-03-14 | Buy | 15,702 | $7.63 | 119,806 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-02-28 | Buy | 29,729 | $9.53 | 283,317 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-02-28 | Buy | 15,104 | $9.53 | 143,941 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-02-18 | Buy | 14,828 | $9.24 | 137,011 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-01-31 | Buy | 125,000 | $11.59 | 1,448,750 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-01-24 | Buy | 1,599 | $10.89 | 17,413 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-01-18 | Buy | 48,488 | $12.41 | 601,736 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2022-01-10 | Buy | 8,867 | $12.93 | 114,650 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2021-12-31 | Buy | 125,000 | $15.75 | 1,968,750 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2021-12-30 | Buy | 50,000 | $15.77 | 788,500 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2021-12-29 | Buy | 75,493 | $14.64 | 1,105,218 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2021-10-29 | Buy | 150,000 | $17.53 | 2,629,500 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2021-09-30 | Buy | 134,543 | $18.65 | 2,509,227 |
|
Spero Therapeutics Inc SPRO
Common Stock, $0.001 par value
|
2021-09-14 | Buy | 2,156 | $18.49 | 39,864 |
| showing 20 of 41 most recent transactions | |||||